Therapeutic Asset Ratings
167 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
shr0302
Non-Small Cell Lung Carcinoma
Chunxia Su
P2
CC
(46)
Sleeping Beauty Transposed Pbl
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P2
CC
(46)
Tcr Transduced T-Cells
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P2
CC
(46)
tqb2101 for
Non-Small Cell Lung Carcinoma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P2
CC
(46)
tqb2102
Non-Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P2
CC
(46)
Yttrium-90-Labeled Fibroblast Activation Protein Inhibitor
Non-Small Cell Lung Carcinoma
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
P2
CC
(46)
Zanidatamab
Non-Small Cell Lung Carcinoma
UNICANCER
P2
CC
(46)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Non-Small Cell Lung Carcinoma
Hummingbird Bioscience
P1/2
CC
(45)
gh21
Non-Small Cell Lung Carcinoma
Suzhou Genhouse Bio Co., Ltd.
P1/2
CC
(45)
ibi318
Non-Small Cell Lung Carcinoma
Hunan Province Tumor Hospital
P2
CC
(43)
1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO-
Non-Small Cell Lung Carcinoma
Nimbus Saturn, Inc.
P1/2
CC
(40)
Afnt-211
Non-Small Cell Lung Carcinoma
Affini-T Therapeutics, Inc.
P1/2
CC
(40)
ak138d1
Non-Small Cell Lung Carcinoma
Akeso
P1/2
CC
(40)
ans014004
Non-Small Cell Lung Carcinoma
Beijing Pearl Biotechnology Limited Liability Company
P1/2
CC
(40)
ans02
Non-Small Cell Lung Carcinoma
Avistone Biotechnology Co., Ltd.
P1/2
CC
(40)
au-007
Non-Small Cell Lung Carcinoma
Aulos Bioscience, Inc.
P1/2
CC
(40)
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
Non-Small Cell Lung Carcinoma
VM Oncology, LLC
P1/2
CC
(40)
Blu-924
Non-Small Cell Lung Carcinoma
Blueprint Medicines Corporation
P1/2
CC
(40)
br790
Non-Small Cell Lung Carcinoma
Shanghai Gopherwood Biotech Co., Ltd.
P1/2
CC
(40)
Ckd-703
Non-Small Cell Lung Carcinoma
Chong Kun Dang Pharmaceutical
P1/2
CC
(40)
cp-383
Non-Small Cell Lung Carcinoma
Tasca Therapeutics
P1/2
CC
(40)
Dositinib Mesylate Tablets
Non-Small Cell Lung Carcinoma
Henan Genuine Biotech Co., Ltd.
P1/2
CC
(40)
Dual-Target Car-Nk Cells
Non-Small Cell Lung Carcinoma
Beijing Biotech
P1/2
CC
(40)
Dupilumab
Non-Small Cell Lung Carcinoma
Centre hospitalier de l'Université de Montréal (CHUM)
P1/2
CC
(40)
exl01
Non-Small Cell Lung Carcinoma
University Hospital, Lille
P1/2
CC
(40)
Showing 76 to 100 of 167 assets
Previous
Page 4 of 7
Next
